CeriBell, Inc. $CBLL Shares Purchased by Rhumbline Advisers

Rhumbline Advisers boosted its position in CeriBell, Inc. (NASDAQ:CBLL) by 26.5% in the 1st quarter, Holdings Channel reports. The firm owned 15,629 shares of the company’s stock after acquiring an additional 3,276 shares during the quarter. Rhumbline Advisers’ holdings in CeriBell were worth $300,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new stake in shares of CeriBell during the fourth quarter worth $43,000. KLP Kapitalforvaltning AS purchased a new stake in CeriBell during the 1st quarter valued at about $36,000. New York State Common Retirement Fund acquired a new stake in CeriBell in the 1st quarter valued at about $67,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in CeriBell in the 4th quarter worth approximately $180,000. Finally, Quantbot Technologies LP acquired a new position in shares of CeriBell during the 1st quarter worth approximately $175,000.

CeriBell Price Performance

Shares of CBLL stock opened at $11.30 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 13.31 and a quick ratio of 12.91. The company has a market capitalization of $414.26 million and a PE ratio of -3.78. The firm’s 50-day moving average is $12.75 and its two-hundred day moving average is $15.92. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $32.75.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. The business had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.52 million. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. CeriBell has set its FY 2025 guidance at EPS. Analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, BTIG Research started coverage on CeriBell in a report on Tuesday, June 24th. They issued a “buy” rating and a $30.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $32.14.

Insider Buying and Selling

In other CeriBell news, CEO Xingjuan Chao sold 25,000 shares of CeriBell stock in a transaction on Monday, July 7th. The stock was sold at an average price of $17.70, for a total value of $442,500.00. Following the sale, the chief executive officer owned 776,022 shares in the company, valued at $13,735,589.40. The trade was a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.10% of the stock is owned by corporate insiders.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.